Shares of Edesa Biotech, Inc. (EDSA) are rising more than 20% Wednesday morning at $6.11.
Today, Edesa said, its Chief Executive Officer, Dr. Par Nijhawan is scheduled to participate in a virtual event to discuss the importance of developing multiple countermeasures to the Covid-19 pandemic, including therapies, like Edesa's EB05 drug candidate, that target the overactive host immune response in Covid-19 patients.
The event is organized by Clinical Trials Ontario in collaboration with the Bureau du Québec à Toronto and the Canadian and International Innovation Partnerships Directorate.
The company's lead candidate, EB05, a monoclonal antibody therapy, is in later stage studies in Acute Respiratory Distress Syndrome (ARDS) in Covid-19 patients.
Last week, Edesa had received approval from the Ministry of Health (INVIMA) in Colombia to expand the study of EB05 in hospitalized COVID-19 patients.
EDSA has been trading in the range of $1.58- $19.1 in the last one year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.